Previous 10 | Next 10 |
Advaxis (NASDAQ: ADXS ): Q2 GAAP EPS of -$1.59 misses by $0.02 . More news on: Advaxis, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Conference call to be held June 11 at 11:00 a.m. ET Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results ...
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET. During the call, Advaxis&...
Appliance Recycling Centers of America (NASDAQ: ARCI ) +19% on Q1 earnings . More news on: Appliance Recycling Centers of America, Inc., PDS Biotechnology Corporation, The Container Store Group, Inc., Stocks on the move, Read more ...
The FDA has removed the partial clinical hold on a Phase 3 clinical trial, AIM2CERV , evaluating Advaxis' (NASDAQ: ADXS ) axalimogene filolisbac (AXAL) in patients with high-risk locally advanced cervical cancer after receiving and reviewing the company's response to its request for addit...
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the ...
Updated data from Phase 1/2 ADXS-PSA study combination arm show prolonged survival in heavily pretreated prostate cancer patients with microsatellite-stable (MSS) disease Updated early findings from Phase 1 ADXS-NEO study show encouraging safety, immunogenicity and clinical signals ...
Advaxis, Inc. (NASDAQ:ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at t...
Advaxis, Inc. (NASDAQ: ADXS) , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in five upcoming industry conferences: BioNJ 9 th Annual BioPartnering Conference Date and Tim...
Gainers: Ocean Power Technologies (NASDAQ: OPTT ) +176% . Netshoes (Cayman) (NYSE: NETS ) +23% . Evogene (NASDAQ: EVGN ) +22% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +21% . DMC Global (NASDAQ: BOOM ) +19% . Fuel Tech (NASDAQ: FTEK ) +18% . VivoPower International (NASDAQ: VVP...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...